Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Colitis, Ulcerative 3Urogenital Neoplasms 2Inflammatory Bowel Diseases 2Crohn Disease 2Colitis 2Carcinoma, Non-Small-Cell Lung 2Takayasu Arteritis 1Recurrence 1Melanoma 1Lung Neoplasms 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

Infliximab 5Certolizumab Pegol 5Adalimumab 3Nivolumab 2MEDI2070 2Educational Status 2CT-P13 2vedolizumab 1secukinumab 1golimumab 1cabozantinib 1Vitamin E 1Vaccines 1Ustekinumab 1Sutures 1Surveys and Questionnaires 1Surgical Instruments 1Standard of Care 1Specimen Handling 1Soybean Oil 1Saline Solution 1Ringer's Lactate 1Proctocolectomy, Restorative 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Platinum Compounds 1Photoplethysmography 1Phlebotomy 1Papillomavirus Vaccines 1Methoxsalen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Crohn Disease × CT-P13 × Clear all
NCT04646187 2025-01-06

FREE

University Medical Center Groningen

Phase 4 Enrolling by invitation
148 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

NCT03452501 2021-02-23

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Hikma Pharmaceuticals LLC

Completed
157 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡